GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®

SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov 17, 2025--

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic® (semaglutide) and Wegovy® (semaglutide) injection pens, available to GoodRx users.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117268209/en/

“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration, home delivery capabilities, and transparent pricing in one seamless experience, GoodRx is creating a higher standard for affordability and trust in weight loss care.”

A Seamless Path to Safe, FDA-Approved GLP-1 Treatment for Weight Loss

GoodRx for Weight Loss is a comprehensive, direct-to-consumer telemedicine subscription built to simplify every step of the GLP-1 treatment journey, from consultation to prescription to fulfillment.

GoodRx for Weight Loss features include:

The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January 2026, with a standard price of $119 beginning on February 1, 2026. Medications are priced separately, allowing customers to only pay for what they need.

Delivering Real Savings on the Most Trusted GLP-1 Medications

Building on its collaboration with Novo Nordisk, GoodRx is now offering savings on Ozempic and Wegovy injection pens to first-time GoodRx users for an introductory price of $199 per month for the first two fills of the two lowest doses (0.25 mg and 0.5 mg), followed by an ongoing price of $349 per month for subsequent fills.* This new reduced pricing makes two of the most in-demand GLP-1 treatments more affordable and accessible for eligible self-paying patients at nearly all pharmacies nationwide.

Whether a consumer already has a prescription or needs help getting started, GoodRx provides a simple, straightforward path to treatment:

Together, these initiatives reinforce GoodRx’s leadership in making trusted, science-backed GLP-1 treatments more affordable and easier to obtain. As the nation’s leading platform for prescription savings, GoodRx is redefining what consumer-first healthcare looks like, delivering safe, affordable, and scalable solutions that help more people start and stay on effective treatment.

*Offer valid through March 31, 2026. Patients using GoodRx to save on their Ozempic or Wegovy prescription for the first time can pay just $199 per month for the first two fills. This introductory price applies to the two lowest doses (0.25 mg and 0.5 mg). After the initial two months, patients will move to the new standard monthly price of $349 per month. Self-pay cost for Ozempic 2.0 mg remains $499.

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website athttps://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of GoodRx for Weight Loss; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®

GoodRx for Weight Loss

CINCINNATI (AP) — The Baltimore Ravens served notice that they have plenty of fight left as they pursue a third straight AFC North title.

The Ravens snapped a two-game losing streak and had what coach John Harbaugh said was their most complete game of the season as they blanked the Cincinnati Bengals 24-0 on Sunday.

Lamar Jackson threw for two touchdowns and the Baltimore defense sacked Joe Burrow three times. Kyle Van Noy and Alohi Gilman teamed up for a 95-yard pick-6 in the fourth quarter that served as the knockout punch, and Burrow was shut out for the first time in his six-year career.

“Complementary football in all three phases, coming off our best week of practice. We’ve had really good weeks of practice, very intentional weeks of practice, and this was another level,” Harbaugh said. “At this point in time, to see that is really what is impressive about these guys.”

The Ravens (7-7) won their fourth straight road game and pulled within a half-game of Pittsburgh in the AFC North. The Steelers host Miami on Monday night.

Baltimore avenged a 32-14 loss to the visiting Bengals on Thanksgiving night.

The Ravens shut out the Bengals for the fourth time. It was the first time the Bengals have been shut out since their 2017 opener, which was also against Baltimore.

“I think we were (ticked) off we lost to them the first time; I’m not going to lie,” Gilman said. "It was good to go out there and just put that on tape and let everyone know that we’re ready to roll.”

Jackson threw first-half TD passes to Rasheen Ali and Zay Flowers and finished 8 of 12 for 150 yards. Derrick Henry rushed for 100 yards on 11 carries, his sixth game of 100 or more this season.

Baltimore's offense was on the field for just 20:41, but scored on three straight drives late in the second quarter and early in the third.

“I believe all of us on offense had good rhythm. It felt like us, and we just have to keep pushing the envelope. We got positive yards and stayed ahead of the sticks,” Jackson said.

Cincinnati (4-10) — eliminated from playoff contention with the loss — drove into Baltimore territory four times but couldn't score.

“It starts with our offense getting shut out. Never saw that coming,” coach Zac Taylor said. “There’s a huge amount of accountability I have to take with that. It’s frustrating to score zero points. That’s unacceptable.”

Burrow completed 25 of 39 passes for 225 yards but went 4 of 10 for 59 yards and was picked off twice when under pressure. The game capped a frustrating week for Burrow, who earlier in the week said he wasn't having fun playing football.

“I mean, I think this is one of the worst games I've played. When your quarterback plays like that, your team is not going to have a chance to win,” said Burrow, who has thrown four interceptions in the last five quarters.

Ja’Marr Chase had 10 receptions for 132 yards.

Midway through the fourth quarter, Burrow drove the Bengals to the Ravens 7. On third-and-goal, Burrow tried to avoid the rush of Baltimore linebacker Tavius Robinson when he was picked off by Van Noy at the 5. Van Noy handed it off at the 16 to Gilman, who went 84 yards up the right sideline for the first defensive touchdown of his five-year career.

Gilman said he wasn't surprised that Van Noy handed the ball off.

“I was actually yelling at him to pitch the ball after he caught it, so it worked out,” he said. “I saved some hamstrings for him. Put it on me. So, shout out to Kyle Van Noy. It was a great play.”

The Ravens extended their lead to 14-0 with 23 seconds left in the first half on Jackson's 28-yard strike to Flowers in the back left corner of the end zone. Bengals safety Geno Stone was late on coverage as the Ravens took only 42 seconds to go 80 yards in five plays.

On the second play of the drive, cornerback DJ Turner had a potential interception deflect off his facemask at the Bengals 17 when Jackson overthrew Mark Andrews.

“To get down there and to get the seven points, take it the 14, two-score game going into halftime — it was a huge drive,” Harbaugh said.

Ravens: LB Teddye Buchanan (knee) left in the first half. CB Chidobe Awuzie (foot) and CB Marlon Humphrey (knee) were injured in the second half. Humphrey returned to the game.

Bengals: WR Charlie Jones (right ankle) came out in the second quarter. TE Noah Fant (right ankle), DT Kris Jenkins Jr. (left ankle) and RT Amarius Mims (right knee) were injured in the second half and did not return.

Ravens: Host New England next Sunday night.

Bengals: At Miami next Sunday.

AP NFL: https://apnews.com/hub/nfl

Baltimore Ravens linebacker Kyle van Noy (53), with safety Alohi Gilman (12) running next to him, returns an interception during the second half of an NFL football game against the Cincinnati Bengals, Sunday, Dec. 14, 2025, in Cincinnati. (AP Photo/Jeff Dean)

Cincinnati Bengals wide receiver Ja'Marr Chase (1) is unable to complete a pass during the first half of an NFL football game against the Baltimore Ravens, Sunday, Dec. 14, 2025, in Cincinnati. (AP Photo/Jeff Dean)

Baltimore Ravens running back Keaton Mitchell (34) runs the ball during the first half of an NFL football game against the Cincinnati Bengals, Sunday, Dec. 14, 2025, in Cincinnati. (AP Photo/Jeff Dean)

Cincinnati Bengals quarterback Joe Burrow (9) reacts after being sacked by Baltimore Ravens linebacker Tavius Robinson during the first half of an NFL football game, Sunday, Dec. 14, 2025, in Cincinnati. (AP Photo/Jeff Dean)

Baltimore Ravens wide receiver Zay Flowers, left, makes a catch for a touchdown past Cincinnati Bengals safety Geno Stone (22) during the first half of an NFL football game, Sunday, Dec. 14, 2025, in Cincinnati. (AP Photo/Carolyn Kaster)